胃癌新辅助化疗免疫治疗后围手术期并发症及其影响因素研究进展

Perioperative complications and risk factors after neoadjuvant immunotherapy for patients with gastric cancer

目前胃切除+D_(2)淋巴结清扫已成为进展期胃癌的标准治疗方案,但胃癌患者的5年生存率仍低于50%。为了改善晚期胃癌患者的预后,新辅助治疗应运而生,并且已经广泛应用于胃癌的治疗。与此同时,以程序性死亡受体1抑制剂为代表的新辅助免疫治疗(neoadjuvant immunotherapy,NAI)在进展期胃癌治疗中开始崭露头角,但新辅助治疗尤其是NAI会不会提高胃癌根治术后的并发症仍是人们所关心的重点。因此本文就胃癌NAI的应用、围手术期并发症情况及手术并发症的影响因素进行阐述。

Currently,gastrectomy+D_(2)lymph node dissection has become the standard treatment for advanced gastric cancer,but the 5-year survival rate of gastric cancer patients is still less than 50%.In order to improve the prognosis of patients with advanced gastric cancer,neoadjuvant therapy has emerged.Neoadjuvant chemotherapy has been widely used in the treatment of gastric cancer.At the same time,neoadjuvant immunotherapy(NAI)represented by PD-1 inhibitors has begun to emerge in the treatment of locally advanced gastric cancer.Whether neoadjuvant therapy,especially NAI,inflicts an increased complications after radical resection of gastric cancer is still a matter of sorne concern.Therefore,this article reviews the application of neoadjuvant therapy for gastric cancer,perioperative complications and influencing factors of surgical complications.